Knockdown of Mgat5 inhibits CD133 + human pulmonary adenocarcinoma cell growth in vitro and in vi o Abstract Purpose: In spite of many therapeutic advances, the prognosis of lung cancer remains poor.
Lung cancer is o en incurable and remains the leading cause of death due to cancer worldwide. Histologically, lung cancer can be divided into four major subtypes: squamous cell carcinoma, adenocarcinoma, small cell carcinoma and large cell carcinoma. Adenocarcinoma is the most common subtype, accounting for almost half of all non-small cell lung carcinomas. Despite continuous e orts to improve the therapeutic response, the overall ve-year survival rate for such tumors is lower than 15% [1, 2] . CD133 is a stem cell marker for cancerous tissues, and it is currently being used, alone or in combination with other markers, for identi cation and isolation of the putative cancer stem cell population from malignant tumors [3] [4] [5] . In lung cancer, there is a rare population of CD133 + cancer stem-like cells able to self-renew and capable of generating unlimited progeny of the di erentiated cells that constitute the major tumor population 6 . Molecular and functional characterization of such a tumorigenic population may provide valuable information to the development of e ective therapies [7] .
N-acetylglucosaminyltransferase V (Mgat5), a key enzyme in the formation of branching of asparagine-linked oligosaccharides, is strongly linked to tumor invasion and metastasis of colon and breast cancers [8] . Several studies have demonstrated the association between Mgat5 activity and increased tumor cell invasiveness [9] [10] [11] . Hirotoshi et al. suggested that expression of Mgat5 is associated with prognosis and histology in non-small cell lung cancers [12] . Oncogenesis increases β1,6-N-acetylglucosaminyltransferase V expression, and its highaf nity galectin ligands promote surface retention of growth receptors with a reduced dependence on UDP-GlcNAc. Of note, Mgat5 −/− tumor cells are less metastatic in vi o and less responsive to cytokines in vitro [13] . Because the function of Mgat5 overlaps with the role of tumor stem cells, we conjectured that Mgat5 may play a role in the activity of tumor stem cells, such as CD133 + lung cancer cells. is study was designed to investigate the expression of Mgat5 and its function in tumor cells isolated from lung adenocarcinomas, which can be separated into two subpopulations by the expression of CD133.
Materials and Methods

Patients and tissue specimens
Ten surgically-resected adenocarcinoma specimens were obtained from patients diagnosed with pulmonary adenocarcinoma who had not undergone radiotherapy or chemotherapy, between 2009 and 2010 at Wuhan University Zhongnan Hospital (Wuhan, China) and Union Medical Hospital (Wuhan, China). e patients ranged in age from 35 to 72 years with an average of 62.3 years. Six patients (60%) were male and four (40%) were female. All studies were performed with the patients' informed consent and approved by the Institutional Review Board of School of Medicine.
Magnetic cell separation (magnetic activated cell sorting, MACS)
Surgical specimens were washed three times and le overnight in DMEM-F12 medium supplemented with antibiotics to avoid contamination (200 IU/mL penicillin, 200µg/mL streptomycin and 5µg/mL amphotericin B).
e tumour tissue specimens were mechanically disrupted and cells were separated by density centrifugation as described previously [7] . Tissue dissociation was carried out by enzymatic digestion using 20µg/mL collagenase II (Gibco-Invitrogen, Carlesbad, CA) for 2h at 37ºC. Recovered cells were cultured in serum-free medium containing 50µg/mL insulin, 100µg/mL apo-transferrin, 10µg/mL putrescine, 0.03mM sodium selenite, 2µM progesterone, 0.6% glucose, 5mM HEPES, 0.1% sodium bicarbonate, 0.4% BSA, glutamine and antibiotics, dissolved in DMEM-F12 medium (Gibco-Invitrogen) and supplemented with 20µg/mL EGF (Epidermal Growth Factor) and 10µg/mL bFGF (basic Fibroblast Growth Factor). A er three subcultures, single cells were prepared with enzymatic digestion, magnetically labeled with anti-CD133 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) in the dark at 4ºC for 30 min and applied to the prepared MS Column (Miltenyi Biotec). CD133 -cells were collected in the ow-through of the column; CD133 + cells bound to the beads were ushed out by applying the plunger supplied with the column.
Flow cytometry e percentage of CD133 expressing cells in the original cell populations, the ow-through fraction, and the ushed-out fraction were analyzed by ow cytometry. Cells were washed twice with phosphate-bu ered saline (PBS) and then were stained at the concentration of 1×10 6 cells per 90µL PBS bu er and 10µL control or speci c antibody. PE-conjugated anti-CD133 was used as the antibody (Miltenyi Biotec). A er 30 min incubation at 4ºC, cells were washed twice with PBS and analysed with a FACScan (Beckman Coulter, Brea, CA).
L-PHA binding assay
CD133 + cells transfected with wild type Mgat5 siRNA or mutant Mgat 5 siRNA were harvested 60 h post-transfection and then washed twice with PBS containing 1% BSA. FITCconjugated leukoagglutinin (L-PHA, Vector Laboratories, Peterborough, UK) was added to a nal concentration of 2.5µg/mL in PBS-BSA, and cells were incubated for 30 min at 4ºC. e cells were collected by centrifugation and then suspended in 1mL PBS-BSA for FACS analysis (Beckman coulter).
RNA Isolation and Real Time Fluorescence uantitation RT-PCR (FQ RT-PCR)
Total RNA was extracted from the cell lysates using TRIZOL (Gibco-Invitrogen). RNA was quantitated by the real-time reverse transcription polymerase chain reaction using the uantiTect TM SYBR Green PCR Handbook Kit (QIAGEN, Valencia, CA). e samples were heated to 95ºC for 10 min, followed by 30 cycles of 95ºC for 10 sec, 56ºC for 20 sec, and 72ºC for 20 sec. e oligonucleotide primers used were as follows: Mgat5 forward: 5'-AGCAGCTCCATGTTACGG -3' , reverse: 5'-GACCAGATTGTCCACCTTT-3'; Beta-actin forward: 5'-TACTGAAGGCCGTGGAC-3' , reverse: 5'-CC TCGTGGCTCCAGTACA-3' (Shanghai Sangon Biological Engineering Technology & Services, Shanghai, China). e relative expression quantities of Mgat5 in each sample were normalized by comparing with that of Beta-actin.
Western blotting
Two million cells were lysed with 500mL SDS-PAGE 1×load-ing bu er, a er boiling for 5 min, samples were separated by 12.5% SDS-PAGE, and transferred to a polyvinylidene di uoride membrane. Skim milk powder solution (10%, w/v) was used in blocking. Mon ºClonal mouse anti-Mgat5 antibody (Abcam, Cambridge, UK) was used at a 1:2000 dilution at RT in TBST bu er (50 mM Tris-HCl, pH 7.6, 137 mM NaCl, 0.1% Tween-20) with 3% fetal bovine serum (Hyclone). e membrane was incubated with primary antibody for 1h at RT, washed three times and then incubated with 1:3000-fold diluted HRP-conjugated goat anti-mouse IgG. Signals were visualized using enhanced chemiluminescence (ECL).
Stable Transfection
As reported, wild-type Mgat5 siRNA and mutant Mgat5 siRNA used in our studies were as follows: siRNA forward: 5'-UCGGGCUUCAAGAUUGCGG-3' , siRNA reverse: 5'-CC GCAAUCUUGAAGCCCGA-3' . siRNAmut forward: 5'-UGCGGCUUCAAGAUUGCGG-3' , siRNAmut reverse: 5'-CCGCAAUCUUGAAGCCGCA -3' [14] (Shanghai Sangon Biological Engineering Technology & Services, Shanghai, China). Transfection of siRNAs were performed with LipofectamineTM 2000 (Gibco-Invitrogen) at a nal concentration of 100nmol/L. Cells were cultured for 48h in complete medium and transferred to complete medium containing 300μg/mL zeocin (Gibco-Invitrogen).
Cell proliferation assay 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) proliferation assay was used to determine the anti-growth e ects of Mgat5 siRNA to CD133 + cells. e cells were resuspended in fresh medium, diluted to 1.25×10 5 cells/ mL, and seeded into four 96-well plates at 100µL per well. After transfection of siRNA, cells were grown for up to 4 days and one plate was used for MTT assay each day. Twenty microliters of MTT (5mg/mL; Sigma, St. Louis, USA) was added to each well, and the cells were incubated at 37ºC for another 4h.
en the culture medium was replaced with 150µL dimethylsulfoxide (Sigma). A er shaking for 10 min, the plate was read for the absorbance at 490nm on a plate reader. e proliferation rate was determined as follows: absorbance of transfected group/absorbance of untransfected group.
Generation of subcutaneous lung cancer xenogra s into SCID mice
For mice xenogra s, CD133 + cells 48h a er transfected with indicated siRNA, diluted in growth factor-containing medium before subcutaneous injection. Four-week-old female SCID mice were used. Cells (100 µl of 1×10 5 /mL) were injected to evaluate the tumorigenic activity of CD133 + cells transfected with Mgat5 speci c siRNA. Mice were monitored to check for the appearance of signs of disease, such as subcutaneous tumors or weight loss due to potential tumor growth in internal sites. The tumor size was measured with calipers and the tumor volume was calculated according to the formula (length×width 2 )/2.
Statistical analysis
Data were expression as the mean ± standard error of the mean (SEM) of at least three independent experiments performed in triplicate. All statistical analyses were performed in the SPSS 11.0 statistical so ware package. Experimental data were analyzed by ANOVA followed by the Student-Newman-Keuls method for multiple comparisons among means. Values of p < 0.05 were considered statistically signi cant.
Results
MACS e ciency detected by FCM
e single cell suspensions were separated into CD133 + and CD133 -cells by magnetic cell separation and then analyzed by ow cytometry for CD133 expression. CD133 + cells were in- frequent, but consistently, detectable in all the patients analyzed (Fig. 1) , which is in accordance with prior reports [7, 15] ; however, there is a good degree of enrichment of the CD133 + subpopulation sorted by magnetic cell separation (Fig. 1) .
To determine the expression of Mgat5 in di erent subpopulations of lung cancer cells, FQRT-PCR and Western blotting were preformed as described above. ese two separate assays gave rise to similar results, indicating that Mgat5 expression was signi cantly higher in CD133 + cells than CD133 -cells.
e FQRT-PCR and Western blot showed the expression of Mgat5 in CD133 + cells was 1.2-fold and 1.4-fold higher than in CD133 -cells, respectively ( Fig. 2A, 2B , 2C, *p<0.05). ese results indicated that Mgat5 was highly expressed in CD133 + cells compared with CD133 -cells.
e plant lectin, leukoagglutinin (L-PHA), binds speci cally to mature Mgat5 products and has been used as a probe for Mgat5-modi ed glycans [16] . CD133 + cells and CD133 -cells were stained with L-PHA (2.5 µg/mL) in PBS-BSA and then analyzed by ow cytometry. e results show that L-PHA binding to Mgat5-modi ed glycans on CD133 + cells (99.1%, MFI=72±5) was signi cantly increased compared with CD133 -cells (89.2%, MFI=12±3) (Fig. 2D, 2E , *p<0.05).
e highly expressed Mgat5-modi ed glycans on CD133 + cells is probably due to the highly expressed Mgat5 in CD133 + cells, which is consistent with the results of FQRT-PCR and Western blot analyses.
Mgat5 siRNA down-regulates the expression of Mgat5 in
As previously reported, wild-type Mgat5 siRNA and mutant Mgat5 siRNA have been synthesized [14] but the ability of siRNA to knockdown the expression of Mgat5 in CD133 + cells has not yet been demonstarted. Here we con rm the interference e ciency by FQRT-PCR, Western blot and L-PHA binding assay. e results of FQRT-PCR show that siRNA was able to interfere with Mgat5 with an interference e ciency of 82%, consistent with the 80% reported previously [14] (Fig.  3A) . e Western blot and L-PHA binding assay show that siRNA e ciently decreases the Mgat5 protein levels and the Mgat5-modi ed glycans production (Fig. 3B, 3C ). e mutant siRNA had no e ect on Mgat5 as shown in Fig. 3 . e siRNA speci c for Mgat5 could e ciently knockdown the expression of Mgat5 in CD133 + cells in vitro.
To determine whether the inhibition of Mgat5 by siRNA affects the growth of CD133 + cell post-transfection, the proliferation of CD133 + cell post-transfection was evaluated by MTT test as described above. e MTT assay showed that the proliferation rate of CD133 + cell treated with siRNA was decreased compared with the untransfected cells (Fig. 4) . At 48h a er transfection, the proliferation rate of CD133 + cell treated with siRNA was signi cantly lower than that of CD133 + cell treated with siRNA mutant (*p<0.05), whereas there was no signi cant di erence between the proliferation rate with siRNA or siRNA mutant at the point 24h a er transfection (Fig. 4) . ese data indicated that speci c siRNA for Mgat5 in uence the proliferation of CD133 + cell in vitro.
o Finally, we performed experiments aiming at evaluating the e ect of Magt5 siRNA on the growth of the CD133 + cells in vi o. As shown in Fig. 5 , the Mgat5 speci c siRNA signicantly suppresses the growth of CD133 + cells in SCID mice, in comparison with all other groups (Fig. 5, p<0.05 ). ese data indicated that speci c siRNA for Mgat5 in uenced the growth of CD133 + cell in vi o.
Discussion
In the last decade, data have been lending support to the idea that tumors contain a small population of cancer stem cells that are responsible for tumor maintenance and spreading. e growing understanding of cancer biology has led to the clear concept that tumors are hierarchically organized and are composed of a heterogeneous population of cells in which a rare population referred to as tumor stem cells (TSC) are at the top of this hierarchy, and play a critical role in the development of cancer. e same phenomena exist in lung cancer; therefore, the identi cation and characterization of the cell populations responsible for lung cancer will contribute signi cantly to the development of new therapeutic strategies and may improve the prognosis of this malignancy.
Although recent evidence suggests the likely presence of cancer stem cells in pulmonary tumors, the phenotype of lung cancer stem cells remains controversial. According to a recent report by Eramo et al., only CD133 + cells serve as a tumorigenic population in lung cancer tissue, being able to reproduce the original tumor in immunocompromised mice, while the CD133 -cancer cell population was completely devoid of tumor-initiating activity [6] . In this study, the rare population of CD133 + cancer stem-like cells were separated from excised Zhou et al. Inhibition of Mgat5 cells suppresses tumor growth pulmonary adenocarcinoma specimens of 10 patients for further analysis. Subsequent study found Mgat5 to be di erentially expressed in pulmonary adenocarcinoma cells and predominantly in CD133 + cells (Fig. 2) . Our data indicate that the distribution of Mgat5 in pulmonary adenocarcinoma tissue was asymmetrical, which was similar to the distribution of galectin-3 in pulmonary adenocarcinoma tissue as reported previously [7] . Taken together, these data indicate that both Mgat5 and galectin-3 are highly expressed in the CD133 + cell and it seems likely that the gene expression pattern is very different between the CD133 + cells and CD133 -cells, which is understandable given their di erent roles in the tumor progress.
Li et al. previously reported that knockdown of Mgat5 inhibited murine breast cancer cell growth in vitro and in vi o, and indicated that tumor growth inhibition in vi o might be due to the direct e ect of Mgat5 speci c shRNA on tumor cells in the early stage and T-cell and macrophage activities at the later stage of tumor development [14] . In this study, Mgat5 speci c siRNA can e ciently knockdown the expression of Mgat5 in CD133 + cells (Fig. 3) , and knockdown of Mgat5 inhibited CD133 + cells growth both in vitro and in vi o (Fig.  4, Fig. 5 ). e immune cells activities were not involved in the reason of inhibited growth of Mgat5 siRNA treated CD133 + cells in vi o in this study because the mice employed were SCID mice. Of note, the MTT assay showed that knockdown of Mgat5 in uence the proliferation of CD133 + cells in vitro (Fig. 4) . e amount of cells xenogra ed into SCID mice was the same, but the proliferation ratio was di erent among each group, which may be the one of the reasons for the inhibition of Mgat5 siRNA treated CD133 + cells growth in vi o.
Knockdown of Mgat5 not only decreased the expression of Mgat5 but also caused defective beta-1,6-GlcNAc branched Nglycan on the cell (Fig. 3) . Hamaguchi et al. e data shown were calculated as mean±s.e.m. (*p<0.05) and data were from three independent experiments (A,C).
linked beta-1,6 -oligosaccharide expression upstream of the action of Mgat5 [17] , at the concentration of 5 mg/mL had no cytotoxicity on murine colorectal cancer cells [18] . ese data suggest that the defective beta-1, 6GlcNAc branched N-glycan expression on the cell has no e ect on cell growth. Taken together, these data suggest that down-regulated expression of Mgat5 in CD133 + cells, but not the defective beta-1, 6-GlcNAc branched N-glycan on the cell, may be the major reason for the decreased proliferation ratio of siRNA-treated CD133 + cells. Mgat5, and its glycan products beta-1,6-GlcNAc branched N-glycans, are tumor-associated glycoproteins commonly increased in malignancies, and their high level expression correlates with disease progression [8, 9, 11] . Furthermore, many studies have demonstrated the association of increased L-PHA binding with increased tumor cell invasiveness. Likewise, cancers of breast, colon, and melanomas show increased levels of beta-1,6-GlcNAc branched N-glycan measured by L-PHA immunohistochemistry [8, 10] . L-PHA reactivity is also increased in atypical hyperplasia and carcinomas of breast compared with normal and benign lesions 10 . In our study, the results of L-PHA binding assay also showed higher reactivity in CD133 + cells than in CD133 -cells (Fig.2D, 2E ) and suggest increased L-PHA reactivity of CD133 + cells, is in accordance with the state of CD133 + cells as cancer stem-like cells.
In conclusion, this study provides concrete experimental evidence that Mgat5 is highly expressed in CD133 + cells from lung adenocarcinoma tissue and contributes to the growth of CD133 + cells. erefore, understanding the role of Mgat5 in the CD133 + cell will yield important insights into such malignancies and delineate novel strategies for disease intervention. + cell treated with indicated siRNA. Proliferation rate was determined as follow: absorbance of transfected CD133 + cells/absorbance of untransfected CD133 + cells. e data shown were calculated as mean±s.e.m. (*p<0.05) and data were from three independent experiments with CD133 + cells were from three individual patients.
FIGURE 5.
+ cells growth in vi o. CD133 + cells from a single patient were transfected with indicated siRNA and xenogra ed into SCID mice as described in the methods. e tumor size was measured with calipers and the tumor volume was calculated according to the formula (length×width 2 )/2.
ere were six mice in each group and the data shown were calculated as mean±s.e.m. (*p<0.05).
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